News: FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS

The Roskamp Institute continues to actively recruit clinical research participants for the treatment of both Alzheimer’s disease and Multiple sclerosis. We are proud to share the following press announcement regarding a clinical trial/potential treatment that Roskamp Institute has been involved in since 2006: “FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to […]

Continue reading